Technology | June 03, 2011

Maquet Cardiovascular Receives 510(K) Clearance To Market Cardioroot Aortic Graft In U.S.

June 3, 2011 -- Maquet Cardiovascular announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market its CardioRoot aortic graft in the United States. A one-piece design, aortic root graft, CardioRoot will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased and damaged aortae. CardioRoot is now commercially available in the United States. CardioRoot’s design mimics the anatomy of the patient’s native aortic root, including the clinically important natural sinuses of valsalva, which supply blood to the heart’s own arteries. CardioRoot’s anatomically correct shape allows easy sewing of valve remnants or a prosthetic valve within the tube, thereby avoiding potential bleeding while shortening surgical procedure time. “The CardioRoot graft is an important option for aortic root repair. The graft wall is supple, allowing better approximation with tissue. The unique properties of the graft material provide ease of suturing and superb predictability of the final geometry,” said Marc W. Gerdisch, M.D., chief of cardiothoracic surgery at Franciscan St. Francis Heart Center in Indianapolis, and a clinical assistant professor of cardiothoracic surgery at Loyola University Medical Center. Dr. Gerdisch is the first cardiothoracic surgeon in the United States to use CardioRoot on a critically ill patient. “The improved hemostasis is an added advantage of CardioRoot for complex aortic root reconstructions, substantially contributing to a dry surgical field at the end of the surgery." For more information: www.maquet.com

Related Content

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Overlay Init